XML 37 R27.htm IDEA: XBRL DOCUMENT v3.19.1
Collaboration arrangements and concentration of credit risk - BMS collaboration - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
May 21, 2015
USD ($)
Aug. 31, 2015
USD ($)
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
Collaboration arrangements          
Revenue     $ 1,136 $ 3,478  
Minimum          
Collaboration arrangements          
Decrease in revenue     1,800    
License revenues from related party          
Collaboration arrangements          
Revenue     557 2,451  
Collaboration revenues from related party          
Collaboration arrangements          
Revenue     579 $ 1,027  
BMS arrangement          
Collaboration arrangements          
Revenue     $ 461   $ 233
License revenue | Bristol Myers Squibb          
Collaboration arrangements          
Upfront payment recorded $ 60,100        
Royalty term after the first commercial sale     10 years    
Average period for completion of pre-clinical phase     4 years    
Average period for completion of clinical development and commercial launch     8 years 6 months    
Percentage of increase in probability of all additional targets     10    
License revenue | Bristol Myers Squibb | First Target Selection          
Collaboration arrangements          
Milestone payments to be received upon achievement     $ 254,000    
License revenue | Bristol Myers Squibb | Second, Third, and Fourth Targets Selection          
Collaboration arrangements          
Target designation payment received   $ 15,000      
License revenue | Bristol Myers Squibb | Fifth through Tenth Targets Selection          
Collaboration arrangements          
Maximum target designation payments to which entitled per agreement     16,500    
License revenue | Bristol Myers Squibb | Other Selected Targets          
Collaboration arrangements          
Milestone payments to be received upon achievement     $ 217,000